Image may be NSFW.
Clik here to view.
Clik here to view.
Rodman starts Affymax at market outperform
Rodman & Renshaw has initiated coverage of Affymax (NASDAQ:AFFY) with a “market outperform” rating and $20 price target, pointing out that the company could soon chip away at Amgen’s 20-year...
View Article
Image may be NSFW.
Clik here to view.
Clik here to view.
Nektar started “buy” at Roth
Roth Capital Partners has initiated coverage of Nektar Therapeutics (NASDAQ:NKTR) with a “buy” rating and $10 price target, citing Nektar’s solid management team, material progress expected on multiple...
View Article
